Norgine, a leading European specialty pharmaceutical company, today announced an exclusive licensing agreement under which ...

A technical analysis of Alnylam stock, explaining the recent correction, and what investors should expect next.

The Nasdaq-100 Index has announced its annual reconstitution, with six new companies being added and six being removed, ...

Alnylam Pharmaceuticals faces near-term headwinds from TTR franchise momentum concerns. Click here to read why ALNY stock is ...

Lululemon Athletica (LULU) to exit the Nasdaq 100 as part of the gauge's annual shakeup, with Seagate (STX) and five others ...

Fintel reports that on December 11, 2025, Stifel maintained coverage of Alnylam Pharmaceuticals (NasdaqGS:ALNY) with a Buy recommendation. Analyst Price Forecast Suggests 20.12% Upside As of December ...

Amy Schulman is the second veteran of the pharmaceutical industry that Elevance has added to its board this year.

An announcement from Alnylam Pharma ( ($ALNY) ) is now available. On December 10, 2025, Alnylam Pharmaceuticals announced it had entered into ...

Gov. Maura Healey is expected to be among those attending a local biopharmaceutical company's announcement of a new ...

Massachusetts Institute of Technology professor Phillip Sharp co-founded Alnylam with several others in 2002. It wasn't Sharp ...

Pfizer has unveiled phase 3 results that could help the company’s hemophilia drug Hympavzi level the playing field in its ...

We'll examine a selection from our screener results. Overview: Alnylam Pharmaceuticals, Inc. focuses on discovering, developing, and commercializing therapeutics based on ribonucleic acid interference ...